Overexpression of EGFR has been shown in both salivary ACC and non-ACC (Agulnik et al, 2007; Ettl et al, 2008), and these findings have provided the motivation for trials with EGFR inhibitor-based therapies. The gene discussed is EGFR; the disease is adrenal cortex carcinoma.